The treatment of pyoderma gangrenosum using etanercept [5]

Journal of the American Academy of Dermatology

Volumn 54, Issue 3 SUPPL. 2, 2006, Pages

  Roy, David B ^a,c   Conte, Eugene T ^a,d   Cohen, David J ^b,d  

^a OHIO UNIVERSITY   (United States)

^b MERCER UNIVERSITY   (United States)

^c Genentech ^*  (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN; DAPSONE; ETANERCEPT; PREDNISONE;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; KIDNEY FUNCTION; LABORATORY TEST; LETTER; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; RECURRENT DISEASE; TREATMENT OUTCOME;

EID: 32644438058     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.10.058     Document Type: Article

References (24)

1. L. Brunsting, W. Goeckerman, and P. O'Leary Pyoderma gangrenosum: clinical and experimental observations in five cases occurring in adults Arch Dermatol Syph 22 1930 655 680
2. F.C. Powell, W.P. Su, and H.O. Perry Pyoderma gangrenosum: classification and management J Am Acad Dermatol 34 1996 395 409
3. R.M. Hurwitz, and J.H. Haseman The evolution of pyoderma gangrenosum: a clinicopathologic correlation Am J Dermatopathol 15 1993 28 33
4. T.T. Provost Pyoderma gangrenosum Adv Stud Med 3 2003 116 118
5. C.A. Charles, T.L. Bialy, A.F. Falabella, W.H. Eaglstein, F.A. Kerdel, and R.S. Kirsner Poor prognosis of arthritis-associated pyoderma gangrenosum Arch Dermatol 140 2004 861 864
6. M.R. Shalaby, M.A. Palladino Jr., S.E. Hirabayashi, T.E. Eessalu, G.D. Lewis, and H.M. Shepard Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha J Leukoc Biol 41 1987 196 204
7. P. Norris, R.N. Poston, D.S. Thomas, M. Thornhill, J. Hawk, and D.O. Haskard The expression of endothelial leukocyte adhesion molecule-1 (ELAM-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in experimental cutaneous inflammation: a comparison of ultraviolet B erythema and delayed hypersensitivity J Invest Dermatol 96 1991 763 770
8. D. Sites A. Terr T. Parslow Basic and clinical immunology 1994 Appleton and Lange Norwalk (CT)
9. Y. Kano, M. Orihara, and T. Shiohara Cellular and molecular dynamics in exercise-induced urticarial vasculitis lesions Arch Dermatol 134 1998 62 67
10. C. Voigtlander, M. Luftl, G. Schuler, and M. Hertl Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) Arch Dermatol 137 2001 1571 1574
11. A.N. Sapadin, and R. Fleischmajer Treatment of scleroderma Arch Dermatol 138 2002 99 105
12. T. Kawakami, S. Ohashi, Y. Kawa, H. Takahama, M. Ito, and Y. Soma Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of Sweet syndrome and patients with active Behcet disease: implication in neutrophil apoptosis dysfunction Arch Dermatol 140 2004 570 574
13. J. Singh, and A. Suruchi AntiTNF-alpha strategy: present status of this therapeutic paradigm Indian J Pharmacol 36 2004 10 14
14. R. Tarnuzzer, and G. Schultz Biochemical analysis of acute and chronic wound environments Wound Rep Reg 4 1996 321 325
15. K. Yamane, H. Ihn, Y. Asano, M. Jinnin, and K. Tamaki Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts J Immunol 171 2003 3855 3862
16. B. Beutler TNF, immunity and inflammatory disease: lessons of the past decade J Investig Med 43 1995 227 235
17. S.J. Baker, and E.P. Reddy Modulation of life and death by the TNF receptor superfamily Oncogene 17 1998 3261 3270
18. T.W. Mak, and W.C. Yeh Signaling for survival and apoptosis in the immune system Arthritis Res 4 Suppl 3 2002 S243 S252
19. J.C. Knight, and D. Kwiatkowski Inherited variability of tumor necrosis factor production and susceptibility to infectious disease Proc Assoc Am Physicians 111 1999 290 298
20. ® (etanercept) Full prescribing information [package insert] 2005 Immunex Corp Thousand Oaks (Calif)
21. M.H. Tan, M. Gordon, O. Lebwohl, J. George, and M.G. Lebwohl Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody Arch Dermatol 137 2001 930 933
22. D.R. Adams, K.B. Gordon, A.G. Devenyi, and M.D. Ioffreda Severe hidradenitis suppurativa treated with infliximab infusion Arch Dermatol 139 2003 1540 1542
23. N.D. Robinson, and J. Guitart Recalcitrant, recurrent aphthous stomatitis treated with etanercept Arch Dermatol 139 2003 1259 1262
24. P.P. Sfikakis Behcet's disease: a new target for anti-tumour necrosis factor treatment Ann Rheum Dis 61 Suppl 2 2002 ii51 ii53